|
|
Prepublished online as a Blood First Edition Paper on January 16, 2003; DOI 10.1182/blood-2002-11-3368.
Previous Article | Table of Contents | Next Article 
Blood, 15 May 2003, Vol. 101, No. 10, pp. 4005-4012
IMMUNOBIOLOGY
2-Microglobulin as a negative regulator of the
immune system: high concentrations of the protein inhibit in vitro
generation of functional dendritic cells
Jin Xie,
Ying Wang,
Muta E. Freeman III,
Bart Barlogie, and
Qing Yi
From the Myeloma Institute for Research and Therapy,
University of Arkansas for Medical Sciences, Little Rock.
Two common features in human immunodeficiency virus infection
and acquired immunodeficiency syndrome, rheumatoid arthritis, and
hematologic malignancies including multiple myeloma are elevated serum
levels of 2-microglobulin ( 2M) and
activation or inhibition of the immune system. We hypothesized that
2M at high concentrations may have a negative impact on
the immune system. In this study, we examined the effects of
2M on monocyte-derived dendritic cells (MoDCs).
The addition of 2M (more than 10 µg/mL) to
the cultures reduced cell yield, inhibited the up-regulation of
surface expression of human histocompatibility leukocyte antigen
(HLA)-ABC, CD1a, and CD80, diminished their ability to activate T
cells, and compromised generation of the type-1 T-cell response induced
in allogeneic mixed-lymphocyte reaction. Compared with control MoDCs,
2M-treated cells produced more interleukin-6 (IL-6),
IL-8, and IL-10. 2M-treated cells expressed
significantly fewer surface CD83, HLA-ABC, costimulatory molecules, and
adhesion molecules and were less potent at stimulating allospecific T
cells after an additional 48-hour culture in the presence of tumor
necrosis factor- and IL-1 . During cell culture, 2M
down-regulated the expression of phosphorylated mitogen-activated protein (MAP) kinases, extracellular signal-related kinase (ERK), and
mitogen-induced extracellular kinase (MEK), inhibited nuclear factor- B (NF- B), and activated signal transducer and activator of
transcription-3 (STAT3) in treated cells, all of which are involved in
cell differentiation and proliferation. Thus, our study demonstrates
that 2M at high concentrations retards the generation of
MoDCs, which may involve down-regulation of major histocompatibility
complex class I molecules, inactivation of Raf/MEK/ERK cascade and
NF- B, and activation of STAT3, and it merits further study to
elucidate the underlying mechanisms.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. v. Rhee
Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System
Clin. Cancer Res.,
March 1, 2007;
13(5):
1353 - 1355.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wang, J. Yang, J. Qian, M. Wezeman, L. W. Kwak, and Q. Yi
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma
Blood,
March 15, 2006;
107(6):
2432 - 2439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Prabhala, P. Neri, J. E. Bae, P. Tassone, M. A. Shammas, C. K. Allam, J. F. Daley, D. Chauhan, E. Blanchard, H. S. Thatte, et al.
Dysfunctional T regulatory cells in multiple myeloma
Blood,
January 1, 2006;
107(1):
301 - 304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ando, A. Shibuya, M. Yasuda, N. Azuma, K. Tsuchiya, T. Akiba, and K. Nitta
Impairment of innate cellular response to in vitro stimuli in patients on continuous ambulatory peritoneal dialysis
Nephrol. Dial. Transplant.,
November 1, 2005;
20(11):
2497 - 2503.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J-E Gottenberg, M Busson, J Cohen-Solal, F Lavie, K Abbed, R P Kimberly, J Sibilia, and X Mariette
Correlation of serum B lymphocyte stimulator and {beta}2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome
Ann Rheum Dis,
July 1, 2005;
64(7):
1050 - 1055.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol.,
August 1, 2004;
76(2):
338 - 351.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|